Monday, May 12, 2008

Testimonials

Will West, Chief Executive Officer, CellCentric

"Avlar have been instrumental in getting CellCentric off the ground and moving rapidly ahead. Specifically the early scientific direction and support has been key, as well as their strong network of contacts to build business relationships. Avlar's ongoing commitment to the company has helped in attracting other investors. Avlar allow a strong sense of ownership to grow within the management, whilst being supportive members of the team through the Board."

Michael Garrison Commercial Director, York Pharma Plc
"Whilst CEO of Molecular SkinCare Ltd, I was grateful for the financial support and considered guidance received from Avlar BioVentures. One cannot overstate the importance of young companies having access to a team of experienced entrepreneurs who have grown businesses successfully in the same sector yet understand that management requires sufficient freedom to thrive. I certainly found Avlar BioVentures to have gotten the balance right as evidenced by Molecular SkinCare's success in being acquired by York Pharma Plc where the combined company now continues to go from strength to strength."

Simon Kerr, Commercial Director, CeNeS Pharma plc

"Avlar BioVentures provided excellent support to TheraSci during its initial growth phase. At the time of TheraSci's formation in 2002, the majority of VC funds were pre-occupied with supporting their existing portfolio companies and had largely moved away from early-stage investments. Very much against this trend, Avlar was prepared to back the management team and business model with early-stage funding and constructive support. Avlar also supported our discussions with GlaxoSmithKline, whilst we were negotiating the acquisition of a novel IV sedative. The successful completion of this deal led directly to the acquisition of TheraSci by CeNeS Pharma in late 2003."